Every 10-Q that Amgen Inc (AMGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AMGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMGN filings page.
Amgen reported higher results for the quarter ended June 30, 2026, with total revenues of $10,054 million versus $9,179 million a year earlier and net income of $2,375 million versus $1,432 million. Diluted EPS was $4.37 compared with $2.65.
Large revenue contributors included Repatha, Prolia, EVENITY, TEPEZZA, BLINCYTO, Nplate, TEZSPIRE, XGEVA, KRYSTEXXA, KYPROLIS, Vectibix, UPLIZNA and IMDELLTRA/IMDYLLTRA. For the first six months, net cash provided by operating activities was $6,191 million, and cash and cash equivalents were $13,989 million, alongside $4.0 billion of new long-term debt issued in the first quarter.
Intangible assets totaled $20,487 million, including TAVNEOS developed-product-technology rights with a $2.4 billion carrying value; the FDA has proposed withdrawing TAVNEOS approval, and Amgen concluded the asset remained recoverable at June 30, 2026. The company is also managing IRA-driven U.S. pricing changes, significant IRS tax disputes and broader macroeconomic and geopolitical pressures.
Amgen Inc. reported higher quarterly results for the three months ended March 31, 2026. Total revenues rose to $8.6 billion from $8.1 billion a year earlier, driven by product sales of $8.2 billion, notably from Repatha, Prolia, EVENITY, TEPEZZA and other key therapies.
Net income increased to $1.8 billion from $1.7 billion, with diluted EPS of $3.34 versus $3.20. Operating income more than doubled to $2.7 billion, helped by lower cost of sales and the absence of prior-year intangible impairments, partly offset by higher R&D spending.
Cash from operating activities rose to $2.2 billion, and cash and cash equivalents reached $12.0 billion, while total assets were $92.5 billion and total debt $58.8 billion. The company continues to face tax disputes with the IRS that could be material and highlighted regulatory scrutiny of TAVNEOS and pricing pressures from U.S. policy changes, including the Inflation Reduction Act.
Amgen Inc. reported stronger Q3 2025 results. Total revenues rose to $9,557 million from $8,503 million a year ago, driven by product sales of $9,137 million. Net income increased to $3,216 million and diluted EPS was $5.93 versus $5.22 last year, as operating income improved to $2,526 million.
Performance was supported by key brands including Prolia, TEPEZZA, EVENITY, Repatha, and Otezla. Other income remained elevated, reflecting unrealized gains on equity investments recorded in the period. Year-to-date, net cash provided by operating activities reached $8,355 million, while cash and cash equivalents were $9,445 million at quarter end. Long-term debt declined to $52,434 million from $56,549 million at year-end.
The effective tax rate increased to 18.0% for the quarter. Amgen recorded an additional $400 million noncash impairment to Otezla developed-product-technology rights in Q3 (total $1.2 billion year-to-date) following updates in Medicare price setting under the IRA.